港股开盘 | 恒指低开0.37%,瑞丽医美首日高开18.75%,港股通"带B新贵"集体飙升
【三大指数】
恒生指数开盘下跌98.19点,跌幅0.37%,报26288.37点;
国企指数开盘下跌57.59点,跌幅0.55%,报10372.94点;
红筹指数开盘上涨6.84点,涨幅0.18%,报3716.75点。
【新股首日】
上市首日,瑞丽医美高开18.75%。
【异动板块】港股通"带B新贵"集体飙升:康宁杰瑞制药-B高开12.88%,诺诚健华-B高开12.17%,沛嘉医疗-B高开11.52%,康方生物-B高开7.53%,亚盛医药-B高开6.21%,启明医疗-B高开6.04%,这6家带"B"字标识的生物科技公司今日起正式纳入港股通股票范围。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.